☰

Brett E. Crawford, Ph.D. - Publications

Affiliations: 
2004 University of California, San Diego, La Jolla, CA 
Area:
Animal Physiology Biology, Biochemistry
Tree Info Similar researchers PubMed Report error

28 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Grover A, Crippen-Harmon D, Nave L, Vincelette J, Wait JCM, Melton AC, Lawrence R, Brown JR, Webster KA, Yip BK, Baridon B, Vitelli C, Rigney S, Christianson TM, Tiger PMN, ... ... Crawford BE, et al. Translational studies of intravenous and intracerebroventricular routes of administration for CNS cellular biodistribution for BMN 250, an enzyme replacement therapy for the treatment of Sanfilippo type B. Drug Delivery and Translational Research. PMID 31942701 DOI: 10.1007/S13346-019-00683-6  0.346
2020 Lawrence R, Prill H, Vachali PP, Adintori EG, de Hart G, Wang RY, Burton BK, Pasquali M, Crawford BE. Characterization of disease-specific chondroitin sulfate non-reducing end accumulation in mucopolysaccharidosis IVA. Glycobiology. PMID 31897472 DOI: 10.1093/Glycob/Cwz109  0.348
2019 Vera MU, Le SQ, Victoroff A, Passage MB, Brown JR, Crawford BE, Polgreen LE, Chen AH, Dickson PI. Evaluation of non-reducing end pathologic glycosaminoglycan detection method for monitoring therapeutic response to enzyme replacement therapy in human mucopolysaccharidosis I. Molecular Genetics and Metabolism. PMID 31630958 DOI: 10.1016/J.Ymgme.2019.09.001  0.301
2019 Li Y, Xu Y, Benitez BA, Nagree MS, Dearborn JT, Jiang X, Guzman MA, Woloszynek JC, Giaramita A, Yip BK, Elsbernd J, Babcock MC, Lo M, Fowler SC, Wozniak DF, ... ... Crawford BE, et al. Genetic ablation of acid ceramidase in Krabbe disease confirms the psychosine hypothesis and identifies a new therapeutic target. Proceedings of the National Academy of Sciences of the United States of America. PMID 31527255 DOI: 10.1073/Pnas.1912108116  0.355
2019 Chen JC, Luu AR, Wise N, Angelis R, Agrawal V, Mangini L, Vincelette J, Handyside B, Sterling HJ, Lo MJ, Wong H, Galicia N, Pacheco G, Van Vleet J, Giaramita A, ... ... Crawford BE, et al. Intracerebroventricular enzyme replacement therapy with Beta-Galactosidase reverses brain pathologies due to GM1 gangliosidosis in mice. The Journal of Biological Chemistry. PMID 31481471 DOI: 10.1074/Jbc.Ra119.009811  0.323
2019 Prill H, Luu A, Yip B, Holtzinger J, Lo MJ, Christianson TM, Yogalingam G, Aoyagi-Scharber M, LeBowitz JH, Crawford BE, Lawrence R. Differential Uptake of NAGLU-IGF2 and Unmodified NAGLU in Cellular Models of Sanfilippo Syndrome Type B. Molecular Therapy. Methods & Clinical Development. 14: 56-63. PMID 31309128 DOI: 10.1016/J.Omtm.2019.05.008  0.368
2019 Yogalingam G, Luu AR, Prill H, Lo MJ, Yip B, Holtzinger J, Christianson T, Aoyagi-Scharber M, Lawrence R, Crawford BE, LeBowitz JH. BMN 250, a fusion of lysosomal alpha-N-acetylglucosaminidase with IGF2, exhibits different patterns of cellular uptake into critical cell types of Sanfilippo syndrome B disease pathogenesis. Plos One. 14: e0207836. PMID 30657762 DOI: 10.1371/Journal.Pone.0207836  0.334
2017 Aoyagi-Scharber M, Crippen-Harmon D, Lawrence R, Vincelette J, Yogalingam G, Prill H, Yip BK, Baridon B, Vitelli C, Lee A, Gorostiza O, Adintori EG, Minto WC, Van Vleet JL, Yates B, ... ... Crawford BE, et al. Clearance of Heparan Sulfate and Attenuation of CNS Pathology by Intracerebroventricular BMN 250 in Sanfilippo Type B Mice. Molecular Therapy. Methods & Clinical Development. 6: 43-53. PMID 28664165 DOI: 10.1016/J.Omtm.2017.05.009  0.316
2016 Yogalingam G, Prill H, Lee A, Christianson T, Tiger PM, Yip BK, Lo MJ, Holtzinger J, Berguig G, Aoyagi-Scharber M, Fitzpatrick P, Lawrence R, Crawford B, LeBowitz JH. Glycosylation independent lysosomal targeting of alpha-n-acetylglucosaminidase confers highly efficient enzyme uptake into critical cellular targets of disease pathogenesis in mucopolysaccharidosis type IIIB Molecular Genetics and Metabolism. 117: S122. DOI: 10.1016/J.Ymgme.2015.12.491  0.305
2014 Kan SH, Aoyagi-Scharber M, Le SQ, Vincelette J, Ohmi K, Bullens S, Wendt DJ, Christianson TM, Tiger PM, Brown JR, Lawrence R, Yip BK, Holtzinger J, Bagri A, Crippen-Harmon D, ... ... Crawford BE, et al. Delivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB. Proceedings of the National Academy of Sciences of the United States of America. 111: 14870-5. PMID 25267636 DOI: 10.1073/Pnas.1416660111  0.325
2014 Lawrence R, Brown JR, Lorey F, Dickson PI, Crawford BE, Esko JD. Glycan-based biomarkers for mucopolysaccharidoses. Molecular Genetics and Metabolism. 111: 73-83. PMID 23958290 DOI: 10.1016/J.Ymgme.2013.07.016  0.522
2013 Lawrence R, Brown JR, Lorey F, Dickson PI, Crawford BE, Esko JD. WITHDRAWN: Glycan-based biomarkers for mucopolysaccharidoses. Disease Markers. PMID 23396297 DOI: 10.3233/DMA-130970  0.366
2012 Bush KT, Crawford BE, Garner OB, Nigam KB, Esko JD, Nigam SK. N-sulfation of heparan sulfate regulates early branching events in the developing mammary gland. The Journal of Biological Chemistry. 287: 42064-70. PMID 23060443 DOI: 10.1074/Jbc.M112.423327  0.661
2012 Lawrence R, Brown JR, Al-Mafraji K, Lamanna WC, Beitel JR, Boons GJ, Esko JD, Crawford BE. Disease-specific non-reducing end carbohydrate biomarkers for mucopolysaccharidoses. Nature Chemical Biology. 8: 197-204. PMID 22231271 DOI: 10.1038/Nchembio.766  0.505
2012 Brown JR, Lawrence R, Al-Mafraji K, Lamanna WC, Beitel JR, Boons G, Esko JD, Crawford BE. Diagnosis and Monitoring of Mucopolysaccharidoses Using Disease-Specific Non-Reducing End Carbohydrate Biomarkers Molecular Genetics and Metabolism. 105: S23. DOI: 10.1016/J.Ymgme.2011.11.035  0.458
2011 Bai X, Nguyen T, Brown J, Glass CA, Duron S, Bhagwat SS, Crawford BE. Abstract 2934: Novel approach for treating neural crest derived tumors: Selective inhibition of ganglioside biosynthesis with small molecules Cancer Research. 71: 2934-2934. DOI: 10.1158/1538-7445.Am2011-2934  0.314
2010 Crawford BE, Garner OB, Bishop JR, Zhang DY, Bush KT, Nigam SK, Esko JD. Loss of the heparan sulfate sulfotransferase, Ndst1, in mammary epithelial cells selectively blocks lobuloalveolar development in mice. Plos One. 5: e10691. PMID 20502530 DOI: 10.1371/Journal.Pone.0010691  0.683
2008 Schuksz M, Fuster MM, Brown JR, Crawford BE, Ditto DP, Lawrence R, Glass CA, Wang L, Tor Y, Esko JD. Surfen, a small molecule antagonist of heparan sulfate. Proceedings of the National Academy of Sciences of the United States of America. 105: 13075-80. PMID 18725627 DOI: 10.1073/Pnas.0805862105  0.704
2007 Brown JR, Crawford BE, Esko JD. Glycan antagonists and inhibitors: a fount for drug discovery. Critical Reviews in Biochemistry and Molecular Biology. 42: 481-515. PMID 18066955 DOI: 10.1080/10409230701751611  0.513
2007 Johnson CE, Crawford BE, Stavridis M, Ten Dam G, Wat AL, Rushton G, Ward CM, Wilson V, van Kuppevelt TH, Esko JD, Smith A, Gallagher JT, Merry CL. Essential alterations of heparan sulfate during the differentiation of embryonic stem cells to Sox1-enhanced green fluorescent protein-expressing neural progenitor cells. Stem Cells (Dayton, Ohio). 25: 1913-23. PMID 17464092 DOI: 10.1634/Stemcells.2006-0445  0.558
2007 Elson-Schwab L, Garner OB, Schuksz M, Crawford BE, Esko JD, Tor Y. Guanidinylated neomycin delivers large, bioactive cargo into cells through a heparan sulfate-dependent pathway. The Journal of Biological Chemistry. 282: 13585-91. PMID 17311923 DOI: 10.1074/Jbc.M700463200  0.677
2005 Bishop JR, Crawford BE, Esko JD. Cell surface heparan sulfate promotes replication of Toxoplasma gondii. Infection and Immunity. 73: 5395-401. PMID 16113255 DOI: 10.1128/Iai.73.9.5395-5401.2005  0.545
2004 Johnson CE, Stavridis MP, Crawford BE, Wilson VA, Esko JD, Smith AG, Gallagher JT, Merry CL. The differentiation of ES cells into neuroectodermal precursors is associated with an increase in the levels and sulfation of heparan sulfate proteoglycans International Journal of Experimental Pathology. 85: A65-A66. DOI: 10.1111/J.0959-9673.2004.390Aa.X  0.545
2002 Zak BM, Crawford BE, Esko JD. Hereditary multiple exostoses and heparan sulfate polymerization. Biochimica Et Biophysica Acta. 1573: 346-55. PMID 12417417 DOI: 10.1016/S0304-4165(02)00402-6  0.647
2001 Bai X, Zhou D, Brown JR, Crawford BE, Hennet T, Esko JD. Biosynthesis of the linkage region of glycosaminoglycans: cloning and activity of galactosyltransferase II, the sixth member of the beta 1,3-galactosyltransferase family (beta 3GalT6). The Journal of Biological Chemistry. 276: 48189-95. PMID 11551958 DOI: 10.1074/Jbc.M107339200  0.529
2001 Bai X, Crawford B, Esko JD. Selection of glycosaminoglycan-deficient mutants Methods in Molecular Biology (Clifton, N.J.). 171: 309-316. PMID 11450242 DOI: 10.1385/1-59259-209-0:309  0.456
2001 Cheung PK, McCormick C, Crawford BE, Esko JD, Tufaro F, Duncan G. Etiological point mutations in the hereditary multiple exostoses gene EXT1: a functional analysis of heparan sulfate polymerase activity. American Journal of Human Genetics. 69: 55-66. PMID 11391482 DOI: 10.1086/321278  0.52
2001 Crawford BE, Olson SK, Esko JD, Pinhal MA. Cloning, Golgi localization, and enzyme activity of the full-length heparin/heparan sulfate-glucuronic acid C5-epimerase. The Journal of Biological Chemistry. 276: 21538-43. PMID 11279150 DOI: 10.1074/Jbc.M100880200  0.513
Show low-probability matches.